Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer.

ABSTRACT:

Importance

The current TNM staging system may not provide adequate information for prognostic purposes and to assess the potential benefits of chemotherapy for patients with stage III colon cancer.

Objective

To develop and validate a pathomics signature to estimate prognosis and benefit from chemotherapy using hematoxylin-eosin (H-E)-stained slides.

Design, setting, and participants

This retrospective prognostic study used data from consecutive patients with histologically confirmed stage III colon cancer at 2 medical centers between January 2012 and December 2015. A total of 114 pathomics features were extracted from digital H-E-stained images from Nanfang Hospital of Southern Medical University, Guangzhou, China, and a pathomics signature was constructed using a lea

SUBMITTER: Jiang W 

PROVIDER: S-EPMC10902777 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature